Related Experiment Video
Updated: Mar 30, 2026

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice
Published on: July 8, 2020
Long-term outcome of IgA nephropathy with minimal change disease: a comparison between patients with and without
Xiao-Wei Li1,2, Shao-Shan Liang2, Wei-Bo Le2
1Department of Nephroloy, Fuyang People's Hospital, 236003, Fuyang, Anhui, China.
Background:
The clinicopathological characteristics, treatment response and long-term outcome of immunoglobulin (Ig)A nephropathy with minimal change disease (MCD-IgAN) are not well defined.
Methods:
Patients with biopsy-proven MCD-IgAN from the Jinling Hospital IgA nephropathy Registry were systematically reviewed and compared with those with IgA nephropathy without minimal change disease (Non-MCD-IgAN).
Results:
We compared data of 247 MCD-IgAN patients and 1,121 Non-MCD-IgAN patients. Compared to Non-MCD-IgAN, MCD-IgAN patients were younger,with male predominance, had higher levels of proteinuria, total cholesterol and estimated glomerular filtration rate (eGFR), lower incidence of hypertension and microhematuria, lower level of serum creatinine, and had less severe glomerular, tubulointerstitial and vascular lesions in renal pathology. In the Non-MCD-IgAN group, 157 patients (14.0 %) reached the renal endpoint and 103 patients (9.2 %) entered end-stage renal disease (ESRD). The 5-,10-, 15- and 20-year cumulative renal survival rates from ESRD, calculated by Kaplan-Meier method, were 95.0, 83.0, 72.9 and 65.4 %, respectively. In the MCD-IgAN group, no patients entered ESRD and only 4 (1.6 %) reached the renal endpoint. Patients with MCD-IgAN had a significantly better renal outcome than Non-MCD-IgAN (p < 0.01). At multivariate Cox analysis, proteinuria >1.0 g/day, hypertension, eGFR <60 ml/min/1.73 m(2), hypoproteinemia and hyperuricemia were independent risk factors of renal survival for Non-MCD-IgAN patients [hazard ratio (HR) 3.43, p < 0.001; HR 1.65, p < 0.05; HR 2.61, p < 0.001; HR 2.40, p < 0.001; HR 2.27, p < 0.001, respectively), but not for patients with MCD-IgAN.
Conclusions:
The long-term outcome of patients with MCD-IgAN is significantly better than that of patients with Non-MCD-IgAN.
Insights
Minimal change disease in IgA nephropathy (MCD-IgAN) patients demonstrates a significantly better long-term renal outcome compared to IgA nephropathy without minimal change disease (Non-MCD-IgAN). This finding highlights key differences in disease progression and prognosis.
Area of Science:
- Nephrology
- Immunology
- Pathology
Background:
- Immunoglobulin A nephropathy (IgAN) is a common primary glomerulonephritis.
- The co-occurrence of minimal change disease (MCD) with IgAN (MCD-IgAN) presents unique clinicopathological characteristics.
- Limited data exists on the treatment response and long-term outcomes for MCD-IgAN.
Purpose of the Study:
- To define the clinicopathological features of MCD-IgAN.
- To compare the treatment response and long-term renal outcomes of MCD-IgAN versus Non-MCD-IgAN.
- To identify risk factors for renal survival in these patient cohorts.
Main Methods:
- Systematic review and comparison of biopsy-proven MCD-IgAN patients (n=247) with Non-MCD-IgAN patients (n=1,121) from a dedicated IgA nephropathy registry.
- Analysis of demographic, clinical, laboratory, and renal pathology data.
- Kaplan-Meier survival analysis and multivariate Cox regression to assess renal survival and identify independent risk factors.
Main Results:
- MCD-IgAN patients were younger, predominantly male, with higher proteinuria and cholesterol, better eGFR, and less severe renal pathology compared to Non-MCD-IgAN.
- Significantly lower rates of renal endpoint (1.6% vs. 14.0%) and no end-stage renal disease (ESRD) were observed in MCD-IgAN patients.
- MCD-IgAN demonstrated a significantly better renal outcome (p < 0.01) with proteinuria, hypertension, and reduced eGFR being independent risk factors only in Non-MCD-IgAN.
Conclusions:
- Patients with MCD-IgAN exhibit a substantially better long-term renal prognosis compared to those with Non-MCD-IgAN.
- The distinct clinical and pathological profiles correlate with improved renal survival in MCD-IgAN.
- Risk factors for renal disease progression differ between MCD-IgAN and Non-MCD-IgAN.
More Related Videos
14:18Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
Published on: October 13, 2023
08:505/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
Published on: July 3, 2013
Related Concept Videos
Acute Kidney Injury III: Clinical Manifestations
Chronic Kidney Disease III: Interprofessional Care
Nephrotic Syndrome I : Introduction
Acute Kidney Injury I: Introduction
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury II: Pathophysiology